- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00784706
Effect of Combined Therapy on Neglect Syndrome in Stroke Patients
August 26, 2012 updated by: Chang Gung Memorial Hospital
The purpose of the current study is to evaluate motor and neglect recovery of stroke patients produced by CIT using kinematic and oculomotor assessment, together with conventional clinical measures.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This project will be carried out using a short term constraint and training protocol targeting at subacute and chronic patients with motor and perceptual deficits.
The outcome measures will include kinematic and oculomotor analyses, which have not been employed yet.
Study Type
Interventional
Enrollment (Actual)
30
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Kwei-shan, Toayuan county, Taiwan
- Chang Gung Memorial Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- a clinical cerebrovascular of right cerebral accident patients
- the age over 18-year-old
- demonstration of Brunnstrom stage III of the affected upper extremity
- patients with perceptual deficits
- no severe cognitive disorder, could understand and follow orders
- no severe equilibrium problems which will influence the intervention
Exclusion Criteria:
- recurrent of the stroke or epilepsy during the intervention
- patients with the neurological or psychical history, for example, alcoholism, drug poisoning or bipolar disorder
- injected the Botox into the affected upper extremity during the past 6 months
- participate in the other interventional study in the same time
- refuse subscribed the informed consent
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CIT with eye-patching
The CIT addressed forced use of the affected UE and restricted the unaffected UE during training.
Shaping skills were delivered while participants were forced to use their affected UE in the mass practice of functional tasks, such as drinking water and opening a jar.
Participants wore a mitt on their unaffected hand and wrist for 6 hours/day during the 3-week training and reported their compliance in a daily log.
Participants were also asked to wear glasses with a patch on the right lens to block the visual stimuli from the right side and force them to receive the stimuli from the left-side visual field.
|
Participants were asked to wear glasses with a patch on the right lens to block the visual stimuli from the right side and force them to receive the stimuli from the left-side visual field.
Other Names:
The CIT addressed forced use of the affected UE and restricted the unaffected UE during training.
Shaping skills were delivered while participants were forced to use their affected UE in the mass practice of functional tasks, such as drinking water and opening a jar.
Participants wore a mitt on their unaffected hand and wrist for 6 hours/day during the 3-week training and reported their compliance in a daily log.
Other Names:
|
Experimental: constraint-induced therapy
The intervention in this group resembled the intervention of the CIT+EP group, except participants did not wear the EP glasses.
|
The CIT addressed forced use of the affected UE and restricted the unaffected UE during training.
Shaping skills were delivered while participants were forced to use their affected UE in the mass practice of functional tasks, such as drinking water and opening a jar.
Participants wore a mitt on their unaffected hand and wrist for 6 hours/day during the 3-week training and reported their compliance in a daily log.
Other Names:
|
Active Comparator: conventional therapy
traditional occupational therapy matched in intensity and duration with the other groups.
The training program included stretching and weight bearing of the affected UE, improving the range of motion of the affected UE, muscle strengthening, and the practice of tasks used for functional training might involve the unaffected UE to assist in the affected UE; for example, stabilizing a bottle while opening its lid or moving pegs into holes on a board.
|
Traditional occupational therapy matched in intensity and duration with the other groups.
The training program included stretching and weight bearing of the affected UE, improving the range of motion of the affected UE, muscle strengthening, and the practice of tasks used for functional training might involve the unaffected UE to assist in the affected UE; for example, stabilizing a bottle while opening its lid or moving pegs into holes on a board.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Catherine Bergego Scale (CBS)
Time Frame: 2008-2009
|
The CBS is a therapist-designed checklist to examine the effect of neglect syndrome on a patient's daily function in 10 real-life situations, such as grooming, dressing, or maneuvering a wheelchair.
A 4-point scale is used in each item, ranging from 0 (no neglect) to 3 (severe neglect).
Patients with a total score of 0 were considered as having no neglect in performing daily activities.
|
2008-2009
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical measures at the impairment, activity, participation levels
Time Frame: 2008-2009
|
2008-2009
|
|
Eye movement analysis
Time Frame: 2008-2009
|
An eye tracker system (Tobii 1750, with 1024 × 768 resolutions a 1 nd 30-Hz sampling rate) was used to record the participant's eye movement by detecting his or her pupil.
To examine the possible improvement in abnormal eye movement after the intervention, the eye movement parameters included the fixation amplitude (the distance between the most left and the most right fixation points), the number of fixation points, and the fixation time in the left area (Left fixation points and Left fixation time).
A fixation point is defined as the gaze point stays in 50 pixels on the screen over 30 ms and can be screened by a fixation filter function in the ClearView 2.0.
A wider fixation amplitude, larger L fixation points, and longer L fixation time represent the alleviated syndrome of neglect.
|
2008-2009
|
kinematic variables
Time Frame: 2008-2009
|
Kinematic analysis was used to detect UE and trunk movement.
A 7-camera motion-analysis system (VICON MX; Oxford Metrics Inc., Oxford, UK)6 was linked to a personal computer to capture the movement of markers.
Reference markers were placed on the seventh cervical vertebra (C7), the fourth thoracic vertebra (T4), the bilateral clavicles, midsternum, and the unaffected side of the acromion, middle of the humerus, lateral epicondyle,styloid process of the ulna and radius, and index nail.
Kinematic variables included reaction time (second), normalized movement time (second), normalized total distance (mm), percentage of movement time where peak velocity (PPV) occurs, and trunk lateral shift.
|
2008-2009
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Ching-yi Wu, ScD, Department of Occupational Therapy, Chang Gung Univ.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2008
Primary Completion (Actual)
October 1, 2009
Study Completion (Actual)
October 1, 2009
Study Registration Dates
First Submitted
October 30, 2008
First Submitted That Met QC Criteria
November 3, 2008
First Posted (Estimate)
November 4, 2008
Study Record Updates
Last Update Posted (Estimate)
August 28, 2012
Last Update Submitted That Met QC Criteria
August 26, 2012
Last Verified
July 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 97-1391B
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cerebrovascular Accidents
-
National Taiwan University HospitalNational Science Council, TaiwanUnknown
-
Fondation Ophtalmologique Adolphe de RothschildCompletedStroke | Cerebrovascular AccidentsFrance
-
MyomoUnknownCerebrovascular AccidentsUnited States
-
Chang Gung Memorial HospitalNational Science Council, Taiwan; National Health Research Institutes, TaiwanCompleted
-
Chang Gung Memorial HospitalNational Science Council, Taiwan; National Health Research Institutes, TaiwanCompletedCerebrovascular AccidentsTaiwan
-
Chang Gung Memorial HospitalNational Science Council, Taiwan; National Health Research Institutes, TaiwanCompletedCerebrovascular AccidentsTaiwan
-
National Taiwan University HospitalNational Science Council, TaiwanUnknownCerebrovascular AccidentsTaiwan
-
Centers for Disease Control and PreventionUnknownAccidents, Traffic
-
Duke UniversityFogarty International Center of the National Institute of Health; Kilimanjaro...Completed
-
Rennes University HospitalCompletedHigh Velocity Transport AccidentsFrance
Clinical Trials on EP
-
eXIthera PharmaceuticalsWithdrawnCovid19 | ThrombopeniaUnited States
-
Sunovion Respiratory Development Inc.Completed
-
National Institute of Allergy and Infectious Diseases...Completed
-
Region StockholmKarolinska InstitutetEnrolling by invitationEpilepsy | Mitochondrial Diseases | Motor Neuron Disease | Metabolic Disease | LHON | Epilepsy in Children
-
BioSig Technologies, Inc.Completed
-
BioSig Technologies, Inc.Completed
-
Boston Scientific CorporationCompleted
-
Esperance Pharmaceuticals IncCompletedAdvanced Solid Tumors | Solid TumorsUnited States
-
John SappNova Scotia Health Authority; Rochester Institute of TechnologyRecruitingMyocardial Infarction | Ventricular TachycardiaCanada
-
Abbott Medical DevicesTerminatedHeart Failure | Cardiac ArrhythmiaUnited States, Spain, Germany, Netherlands, Estonia, Canada, Austria, Australia